Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron wins FDA approval to challenge Ipsen for rare bone disease market
Regeneron
Biopharmaceutical company
Company Info
Recent News
US FDA approves Regeneron's rare bone disorder drug
US FDA approves Regeneron's rare bone disorder drug